ECSP078051A - Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas - Google Patents
Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicasInfo
- Publication number
- ECSP078051A ECSP078051A EC2007008051A ECSP078051A ECSP078051A EC SP078051 A ECSP078051 A EC SP078051A EC 2007008051 A EC2007008051 A EC 2007008051A EC SP078051 A ECSP078051 A EC SP078051A EC SP078051 A ECSP078051 A EC SP078051A
- Authority
- EC
- Ecuador
- Prior art keywords
- treatment
- inhibitors
- cholesterol absorption
- azetidinone
- new derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuestos de fórmula (I) (donde los grupos variables son como los definidos aquí), sales farmacéuticamente aceptables, solvatos, solvatos de tales sales o profármacos de los mismos y su uso como inhibidores de la absorción del colesterol para el tratamiento de la hiperlipidemia son descritos. Los procesos para su fabricación y las composiciones farmacéuticas que los contienen también son descritos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0501464 | 2005-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP078051A true ECSP078051A (es) | 2008-01-23 |
Family
ID=37570735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2007008051A ECSP078051A (es) | 2005-06-22 | 2007-12-26 | Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas |
Country Status (20)
Country | Link |
---|---|
US (1) | US7906502B2 (es) |
EP (1) | EP1896459A4 (es) |
JP (1) | JP2008546774A (es) |
KR (1) | KR20080017475A (es) |
CN (1) | CN101243076A (es) |
AR (1) | AR057072A1 (es) |
AU (1) | AU2006259898B2 (es) |
BR (1) | BRPI0612109A2 (es) |
CA (1) | CA2610036A1 (es) |
EC (1) | ECSP078051A (es) |
IL (1) | IL187741A0 (es) |
MX (1) | MX2007016398A (es) |
MY (1) | MY148538A (es) |
NO (1) | NO20076138L (es) |
RU (1) | RU2409572C2 (es) |
SA (1) | SA06270197B1 (es) |
TW (1) | TW200728302A (es) |
UY (1) | UY29613A1 (es) |
WO (1) | WO2006137797A1 (es) |
ZA (1) | ZA200710604B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1699759B1 (en) | 2003-12-23 | 2010-10-20 | AstraZeneca AB | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
AR057072A1 (es) | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
CA2675312A1 (en) * | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | 1-biarylazetidinone derivative |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
CA2754384A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
US8785608B2 (en) | 2009-08-26 | 2014-07-22 | Sanofi | Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
DK1413331T3 (da) | 2001-01-26 | 2007-12-10 | Schering Corp | Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivatoren fenofibrat og sterolabsorptionsinhibitoren ezetimib til vaskulære indikationer |
TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
MXPA04002572A (es) | 2001-09-21 | 2004-05-31 | Schering Corp | Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol. |
US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
MXPA04002573A (es) | 2001-09-21 | 2004-06-18 | Schering Corp | Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol. |
GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US6761509B2 (en) | 2002-07-26 | 2004-07-13 | Jan Erik Jansson | Concrete module for retaining wall and improved retaining wall |
US6960047B2 (en) | 2002-08-02 | 2005-11-01 | Innovative Technology Application, Inc. | Protection barrier apparatus |
EP1562582A1 (en) | 2002-11-06 | 2005-08-17 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of demyelination |
ATE406364T1 (de) | 2003-03-07 | 2008-09-15 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
EP1626954A2 (en) | 2003-05-05 | 2006-02-22 | Ranbaxy Laboratories, Ltd. | Process for the preparation of trans-isomers of diphenylazetidinone derivatives |
WO2004107958A2 (en) | 2003-05-30 | 2004-12-16 | Schering Corporation | Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
US7002008B2 (en) | 2003-06-16 | 2006-02-21 | Bomi Patel Framroze | Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one |
JP2005015434A (ja) | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
EP1660456A2 (en) | 2003-08-25 | 2006-05-31 | Microbia Inc. | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
US20070161577A1 (en) | 2003-08-28 | 2007-07-12 | Martinez Eduardo J | Tethered dimers and trimers of 1,4-diphenylazetidin-2-ones |
EP1522541A1 (en) | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Novel hypocholesterolemic compounds |
EP1682117A1 (en) | 2003-10-30 | 2006-07-26 | Merck & Co., Inc. | 2-azetidinones as anti-hypercholesterolemic agents |
WO2005042692A2 (en) | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
JP2007510659A (ja) | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置 |
PT1682499E (pt) | 2003-11-10 | 2007-11-05 | Microbia Inc | 4-biarilil-1-fenilazetidin-2-onas |
EP1687287A1 (en) | 2003-11-24 | 2006-08-09 | Hetero Drugs Limited | A novel process for ezetimibe intermediate |
CN1913892A (zh) | 2003-12-17 | 2007-02-14 | 大日本住友制药株式会社 | 药物组合物及联合药物 |
GB0329778D0 (en) | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
AU2004308332B2 (en) | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
EP1699759B1 (en) | 2003-12-23 | 2010-10-20 | AstraZeneca AB | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
WO2005062897A2 (en) | 2003-12-23 | 2005-07-14 | Dr. Reddy's Laboratories Ltd. | Polymorphs of ezetimibe and processes for the preparation thereof |
WO2005066120A2 (en) | 2003-12-30 | 2005-07-21 | Ranbaxy Laboratories Limited | Process for asymmetric synthesis of hydroxy-alkyl substituted azetidinone derivatives |
WO2005069900A2 (en) | 2004-01-16 | 2005-08-04 | Merck & Co., Inc. | Npc1l1 (npc3) and methods of identifying ligands thereof |
RS20060437A (en) | 2004-01-20 | 2008-11-28 | Panacea Boitec Ltd., | Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof |
KR100725758B1 (ko) * | 2004-03-30 | 2007-06-08 | 삼성광주전자 주식회사 | 전동 송풍기 및 이를 이용한 자동차용 전동 과급기 |
DE102004025072A1 (de) | 2004-05-21 | 2005-12-15 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten |
PT1756049E (pt) | 2004-05-21 | 2007-12-17 | Sanofi Aventis Deutschland | Processo para a preparação de derivados de 1,4-difenilazetidinona |
WO2006017257A2 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Azetidinone derivatives |
US20060046996A1 (en) | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
WO2006039334A1 (en) | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
JP2007526251A (ja) | 2004-12-03 | 2007-09-13 | テバ ファーマシューティカル インダストリーズ リミティド | エゼチミベ多形体 |
CA2591564A1 (en) | 2004-12-20 | 2006-06-29 | Schering Corporation | Process for the synthesis of azetidinones |
IL166149A0 (en) | 2005-01-05 | 2006-01-15 | Hadasit Med Res Service | Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity |
WO2006086562A2 (en) | 2005-02-09 | 2006-08-17 | Microbia, Inc. | Phenylazetidinone derivatives |
US20090186834A1 (en) | 2005-03-24 | 2009-07-23 | Microbia, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
US8361999B2 (en) | 2005-04-04 | 2013-01-29 | Pontificia Universidad Catolica De Chile | Methods of treating cholesterol gallstone disease with ezetimibe |
JP2008539255A (ja) | 2005-04-26 | 2008-11-13 | マイクロビア インコーポレーテッド | 高コレステロール血症のための4−ビアリーリル−1−フェニルアゼチジン−2−オングルクロニド誘導体 |
US20090131395A1 (en) | 2005-05-05 | 2009-05-21 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
WO2006122186A2 (en) | 2005-05-10 | 2006-11-16 | Microbia, Inc. | 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia |
MX2007014172A (es) | 2005-05-11 | 2008-04-02 | Microbia Inc | Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos. |
WO2006124713A2 (en) | 2005-05-13 | 2006-11-23 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-ones |
AU2006249905A1 (en) | 2005-05-25 | 2006-11-30 | Microbia, Inc. | Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids |
CN101198338A (zh) | 2005-06-15 | 2008-06-11 | 默克公司 | 抗高胆固醇血化合物 |
WO2006134604A1 (en) | 2005-06-15 | 2006-12-21 | Hetero Drugs Limited | Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor |
UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
CA2613239A1 (en) | 2005-06-22 | 2006-12-28 | Manne Satyanarayana Reddy | Improved process for the preparation of ezetimibe |
AR057380A1 (es) | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
AR056866A1 (es) | 2005-06-22 | 2007-10-31 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto |
AR054482A1 (es) | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
AR057072A1 (es) | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
AR057383A1 (es) * | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
EP1741427A1 (en) | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
WO2007008529A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc | Celullar cholesterol absorption modifiers |
JP2009503049A (ja) | 2005-08-01 | 2009-01-29 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 新規な置換アゼチジノン |
WO2007016643A2 (en) | 2005-08-01 | 2007-02-08 | Mount Sinai School Of Medicine Of New York University | A method for extending longevity using npc1l1 antagonists |
WO2007017705A1 (en) | 2005-08-09 | 2007-02-15 | Glenmark Pharmaceuticals Limited | Process for the preparation of azetidinones |
US20070049748A1 (en) | 2005-08-26 | 2007-03-01 | Uppala Venkata Bhaskara R | Preparation of ezetimibe |
CA2616058A1 (en) | 2005-09-08 | 2007-03-15 | Vinod Kumar Kansal | Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe |
TW200806623A (en) | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
PE20070824A1 (es) | 2005-11-15 | 2007-08-24 | Takeda Pharmaceutical | Composicion farmaceutica que contiene lapaquistat y ezetimibe en el tratamiento de hiperlipidemia |
DE102005055726A1 (de) | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US7498431B2 (en) | 2005-12-01 | 2009-03-03 | Bomi Patel Framroze | Process for the preparation of chiral azetidinones |
HU0501164D0 (en) | 2005-12-20 | 2006-02-28 | Richter Gedeon Vegyeszet | New industrial process for the production of ezetimibe |
WO2007075702A2 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
AR060623A1 (es) * | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
US20080070890A1 (en) * | 2006-09-15 | 2008-03-20 | Burnett Duane A | Spirocyclic Azetidinone Compounds and Methods of Use Thereof |
CA2675312A1 (en) * | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | 1-biarylazetidinone derivative |
-
2006
- 2006-06-20 AR ARP060102611A patent/AR057072A1/es not_active Application Discontinuation
- 2006-06-20 MY MYPI20062928A patent/MY148538A/en unknown
- 2006-06-21 RU RU2007147340/04A patent/RU2409572C2/ru not_active IP Right Cessation
- 2006-06-21 SA SA6270197A patent/SA06270197B1/ar unknown
- 2006-06-21 WO PCT/SE2006/000766 patent/WO2006137797A1/en active Application Filing
- 2006-06-21 AU AU2006259898A patent/AU2006259898B2/en not_active Ceased
- 2006-06-21 MX MX2007016398A patent/MX2007016398A/es not_active Application Discontinuation
- 2006-06-21 BR BRPI0612109A patent/BRPI0612109A2/pt not_active IP Right Cessation
- 2006-06-21 CN CNA2006800294761A patent/CN101243076A/zh active Pending
- 2006-06-21 EP EP06747955A patent/EP1896459A4/en not_active Withdrawn
- 2006-06-21 KR KR1020087001032A patent/KR20080017475A/ko not_active Application Discontinuation
- 2006-06-21 CA CA002610036A patent/CA2610036A1/en not_active Abandoned
- 2006-06-21 UY UY29613A patent/UY29613A1/es unknown
- 2006-06-21 JP JP2008518088A patent/JP2008546774A/ja active Pending
- 2006-06-21 US US11/993,463 patent/US7906502B2/en not_active Expired - Fee Related
- 2006-06-22 TW TW095122513A patent/TW200728302A/zh unknown
-
2007
- 2007-11-28 IL IL187741A patent/IL187741A0/en unknown
- 2007-11-28 NO NO20076138A patent/NO20076138L/no not_active Application Discontinuation
- 2007-12-05 ZA ZA200710604A patent/ZA200710604B/xx unknown
- 2007-12-26 EC EC2007008051A patent/ECSP078051A/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL187741A0 (en) | 2008-03-20 |
JP2008546774A (ja) | 2008-12-25 |
BRPI0612109A2 (pt) | 2016-09-06 |
RU2409572C2 (ru) | 2011-01-20 |
NO20076138L (no) | 2008-02-27 |
CA2610036A1 (en) | 2006-12-28 |
AU2006259898A1 (en) | 2006-12-28 |
CN101243076A (zh) | 2008-08-13 |
TW200728302A (en) | 2007-08-01 |
KR20080017475A (ko) | 2008-02-26 |
US20100168039A1 (en) | 2010-07-01 |
AU2006259898B2 (en) | 2010-08-05 |
MX2007016398A (es) | 2008-03-05 |
ZA200710604B (en) | 2008-12-31 |
RU2007147340A (ru) | 2009-07-27 |
AR057072A1 (es) | 2007-11-14 |
SA06270197B1 (ar) | 2010-06-20 |
WO2006137797A1 (en) | 2006-12-28 |
UY29613A1 (es) | 2007-01-31 |
EP1896459A1 (en) | 2008-03-12 |
MY148538A (en) | 2013-04-30 |
US7906502B2 (en) | 2011-03-15 |
EP1896459A4 (en) | 2010-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP078052A (es) | Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas | |
ECSP078051A (es) | Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas | |
UY28691A1 (es) | Derivados de difenilazetidona | |
UY27882A1 (es) | Compuestos quimicos | |
ECSP088099A (es) | Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas | |
UY28695A1 (es) | Derivados de difenilazetidona | |
ECSP088114A (es) | Nuevos derivados de la 2-azetidinona y su uso como inhibidores de absorción del colesterol para el tratamiento de hiperlipidemia | |
ECSP088103A (es) | Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia | |
ECSP078053A (es) | Nuevos derivados de 2-azetidinona útiles en el tratamiento de condiciones de hiperlipidemia | |
UY28876A1 (es) | Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central | |
UY29767A1 (es) | Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones | |
UY29414A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
DOP2011000076A (es) | Derivados de heteroaril amidas y su uso como activadores de glucoquinasa | |
UY30470A1 (es) | Compuestos heteroarilos de cinco heteroatomos sustituidos con fenilo conteniendo nitrogeno, composiciones farmacéuticas y aplicaciones. | |
CU23464B7 (es) | (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
ECSP088329A (es) | Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 | |
ECSP088590A (es) | Derivados de aminoácido multicíclicos y sus métodos de uso | |
ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
UY29648A1 (es) | Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
UY30835A1 (es) | 8-alquinilxantinas y derivados | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
CL2007003223A1 (es) | Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades. | |
HN2003000162A (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen. | |
UY29631A1 (es) | Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica | |
DOP2005000151A (es) | Nuevos inhibidores de la recaptacion de norepinefrina de quinoxalinona para el tratamiento de trastonos del sisitema nervioso central. |